You are Trying to View a Free Article

Daily News You Can't Find Anywhere Else

Genentech Completes iNeST Facility in Oregon


Industry Segment: Pharmaceutical & Biotech | Word Count: 135 Words
Attachment: Map

Genentech, the first publicly owned biotechnology company, recently completed an individualized neoantigen-specific immunotherapy (iNeST) facility on its campus in Hillsboro, Oregon. Using proprietary algorithms, the iNeST process involves DNA extraction from an individual patient's tumor cells and sequences, according to the company.

Subscribe Now! All Fields Required...

Standard Membership - Free